Qiu Jia-Jun, Yan Jing-Bin
Shanghai Children's Hospital, Shanghai Institute of Medical Genetics, Shanghai Jiao Tong University School of Medicine, 24/1400 West Beijing Rd., Shanghai, 200040, China.
Key Laboratory of Embryo Molecular Biology, Ministry of Health of China and Shanghai Key Laboratory of Embryo and Reproduction Engineering, Shanghai, 200040, China.
Tumour Biol. 2015 Sep;36(9):7175-83. doi: 10.1007/s13277-015-3448-5. Epub 2015 Apr 17.
Colorectal cancer (CRC), one of the most malignant cancers, is currently the fourth leading cause of cancer deaths worldwide. Recent studies indicated that long non-coding RNAs (lncRNAs) could be robust molecular prognostic biomarkers that can refine the conventional tumor-node-metastasis staging system to predict the outcomes of CRC patients. In this study, the lncRNA expression profiles were analyzed in five datasets (GSE24549, GSE24550, GSE35834, GSE50421, and GSE31737) by probe set reannotation and an lncRNA classification pipeline. Twenty-five lncRNAs were differentially expressed between CRC tissue and tumor-adjacent normal tissue samples. In these 25 lncRNAs, patients with higher expression of LINC01296, LINC00152, and FIRRE showed significantly better overall survival than those with lower expression (P < 0.05), suggesting that these lncRNAs might be associated with prognosis. Multivariate analysis indicated that LINC01296 overexpression was an independent predictor for patients' prognosis in the test datasets (GSE24549, GSE24550) (P = 0.001) and an independent validation series (GSE39582) (P = 0.027). Our results suggest that LINC01296 could be a novel prognosis biomarker for the diagnosis of CRC.
结直肠癌（CRC）是最恶性的癌症之一，目前是全球癌症死亡的第四大主要原因。最近的研究表明，长链非编码RNA（lncRNAs）可能是强大的分子预后生物标志物，可完善传统的肿瘤-淋巴结-转移分期系统，以预测CRC患者的预后。在本研究中，通过探针集重新注释和lncRNA分类流程，对五个数据集（GSE24549、GSE24550、GSE35834、GSE50421和GSE31737）中的lncRNA表达谱进行了分析。CRC组织与肿瘤邻近正常组织样本之间有25种lncRNAs差异表达。在这25种lncRNAs中，LINC01296、LINC00152和FIRRE表达较高的患者总体生存率显著高于表达较低的患者（P < 0.05），表明这些lncRNAs可能与预后相关。多变量分析表明，LINC01296过表达是测试数据集（GSE24549、GSE24550）（P = 0.001）和独立验证系列（GSE39582）（P = 0.027）中患者预后的独立预测因子。我们的结果表明，LINC01296可能是一种用于CRC诊断的新型预后生物标志物。
